Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Nadia WaheedChief Medical Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 06/03 | 06/05 | 14,828 sh | $8.27 | $122,627.56 | −4.7% |
Jeffrey S. HeierChief Scientific Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 05/26 | 05/28 | 3,018 sh | $8.20 | $24,747.6 | −0.9% |
Pravin DugelSEE REMARKS | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 05/26 | 05/28 | 21,156 sh | $8.20 | $173,479.2 | −0.8% |
Peter KaiserChief Development Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 05/26 | 05/28 | 2,967 sh | $8.20 | $24,329.4 | −1.1% |
Sanjay NayakChief Strategy Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 05/26 | 05/28 | 1,858 sh | $8.20 | $15,235.6 | −0.6% |
Jeffrey S. HeierChief Scientific Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/23 | 02/25 | 3,057 sh | $8.28 | $25,311.96 | −0.9% |
Pravin DugelSEE REMARKS | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/23 | 02/25 | 20,056 sh | $8.28 | $166,063.68 | −0.7% |
Peter KaiserChief Development Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/23 | 02/25 | 2,810 sh | $8.28 | $23,266.8 | −1.0% |
Sanjay NayakChief Strategy Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/23 | 02/25 | 1,759 sh | $8.28 | $14,564.52 | −0.5% |
Richard L. Md LindstromDirector | Ocular TherapeutixOCUL | Open-market buy | 02/20 | 02/24 | 60,229 sh | $7.66 | $461,354.14 | +32.3% |
Nadia WaheedChief Medical Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/20 | 02/24 | 3,510 sh | $7.74 | $27,167.4 | −1.1% |
Pravin DugelSEE REMARKS | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/12 | 02/17 | 124,882 sh | $9.04 | $1,128,933.28 | −4.0% |
Ocular TherapeutixOCUL | Open-market sale | 02/12 | 02/17 | 11,446 sh | $9.04 | $103,471.84 | −3.0% | |
Sanjay NayakChief Strategy Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/12 | 02/17 | 10,348 sh | $9.04 | $93,545.92 | −3.0% |
Nadia WaheedChief Medical Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 02/12 | 02/17 | 7,863 sh | $9.04 | $71,081.52 | −2.4% |
Ocular TherapeutixOCUL | Open-market sale | 02/02–02/04 | 02/04 | 11,490 sh2 trades | $8.82avg. | $101,397.6 | −3.0% | |
Jeffrey S. HeierChief Scientific Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 25/11/24 | 25/11/26 | 3,469 sh | $12.04 | $41,766.76 | −1.4% |
Pravin DugelSEE REMARKS | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 25/11/24 | 25/11/26 | 19,530 sh | $12.04 | $235,141.2 | −0.6% |
Peter KaiserChief Development Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 25/11/24 | 25/11/26 | 3,007 sh | $12.02 | $36,144.14 | −1.5% |
Sanjay NayakChief Strategy Officer | Ocular TherapeutixOCUL | Open-market sale10b5-1 plan | 25/11/24 | 25/11/26 | 1,878 sh | $12.04 | $22,611.12 | −0.7% |